Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Operating Leases (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Operating Leases data on record, last reported at $4.6 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 27.16% year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.6 million, down 27.16%, while the annual FY2024 figure was $4.4 million, 2954.17% up from the prior year.
  • Operating Leases reached $4.6 million in Q3 2025 per GOSS's latest filing, down from $4.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $7.8 million in Q2 2022 and bottomed at $144000.0 in Q4 2023.
  • Average Operating Leases over 4 years is $4.6 million, with a median of $4.8 million recorded in 2025.
  • Peak YoY movement for Operating Leases: tumbled 95.82% in 2023, then surged 2954.17% in 2024.
  • A 4-year view of Operating Leases shows it stood at $3.4 million in 2022, then crashed by 95.82% to $144000.0 in 2023, then soared by 2954.17% to $4.4 million in 2024, then rose by 5.03% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.6 million in Q3 2025, $4.8 million in Q2 2025, and $4.2 million in Q1 2025.